Opioids Need Post-Marketing Data To Inform Abuse-Deterrent Claims, FDA Panel Says
This article was originally published in The Pink Sheet Daily
Pfizer’s extended-release opioid Troxyca ER receives advisory committee recommendation for approval and two of three abuse-deterrent labeling claims, but members also want post-marketing data to help make future decisions.
You may also be interested in...
Panelists at US FDA advisory committee on Inspirion's RoxyBond note reservations about abuse-deterrent claims absent more real-world data on how they work; FDA's Staffa suggests agency is eager to see how well premarket work predicts postmarket experience – though the data are far from being available.
FDA approved Pfizer’s oxycodone/naltrexone extended release opioid with abuse deterrent claims similar to Embeda. That isn’t the label FDA’s advisory committee supported.
As Egalet's Arymo ER heads to panel, agency tries to head off discussion about whether it should be approving new opioid products and whether longer clinical efficacy trials should be demanded.